Thioxanthine Derivatives for Selective MPO Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with elevated myeloperoxidase (MPO) levels, such as multiple sclerosis, chronic obstructive pulmonary disease, and atherosclerosis, lack effective inhibitors that can selectively target MPO while maintaining brain permeability and stability.
Innovation Solution
Development of novel thioxanthine derivatives that exhibit high selectivity towards MPO, improved inhibitory activity, brain permeability, solubility, and half-life, as described in the compounds of Formula (I), which are designed to inhibit MPO activity effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for conditions associated with elevated MPO levels, then existing therapeutic options are available, but effective inhibitors that can selectively target MPO while maintaining brain permeability and stability are lacking
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of thioxanthine derivatives through varying substituents at different positions (R1, R2, R3, R4, R9, n) to optimize the balance between MPO selectivity, brain permeability, and stability. This includes changing molecular weight, lipophilicity, and steric properties to achieve the desired pharmacokinetic profile while maintaining target selectivity
Solution Approach 2:
The invention employs composite molecular structures combining the thioxanthine core with various heteroaromatic ring systems (pyridine, pyrimidine, triazine, indole, benzimidazole) and substituent groups to create compounds that simultaneously achieve MPO selectivity, brain penetration, and metabolic stability through synergistic structural features
2Reliability
If novel thioxanthine derivatives are designed to inhibit MPO activity effectively, then inhibitory activity is improved, but maintaining a balance between selectivity, brain permeability, solubility, and half-life becomes challenging
Solution Approach 1:
The patent segments the molecular optimization into distinct structural components: the thioxanthine core (for MPO binding), heteroaromatic ring systems (for selectivity enhancement), and various substituents (for pharmacokinetic optimization). This modular approach allows independent optimization of each component to achieve the desired balance of properties
Solution Approach 2:
The thioxanthine derivative structure is designed to serve multiple functions simultaneously: MPO inhibition through heme interaction, brain permeability through optimized lipophilicity, solubility through polar substituents, and metabolic stability through strategic placement of electron-withdrawing groups. The core structure acts as a multi-functional platform addressing all requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel thioxanthine derivatives provide therapeutic benefits by selectively inhibiting MPO, potentially alleviating inflammatory and atherosclerotic conditions, slowing disease progression, and reducing the risk of acute and chronic inflammatory disorders.
Implementation Method 1
The present invention relates to novel thioxanthine derivatives, processes for their preparation, compositions containing them and their use in therapy... Myeloperoxidase (MPO) is a heme-containing enzyme... The novel thioxanthine derivatives provide therapeutic benefits by selectively inhibiting MPO
Data Source
AI summary
There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.